United Services Automobile Association Purchases New Shares in Halozyme Therapeutics, Inc. $HALO

Key Points

• United Services Automobile Association acquired 8,540 shares of Halozyme Therapeutics valued at approximately $545,000 during the first quarter.
• Halozyme Therapeutics reported $1.54 EPS for the last quarter, exceeding analyst estimates of $1.23, with a revenue of $325.72 million, marking a 40.8% increase year-over-year.
• Analysts have revised their price targets for Halozyme Therapeutics, with Morgan Stanley increasing it from $75.00 to $80.00 and Zacks Research upgrading to a "strong-buy" rating.

United Services Automobile Association acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 8,540 shares of the biopharmaceutical company's stock, valued at approximately $545,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Great Lakes Advisors LLC raised its position in shares of Halozyme Therapeutics by 153.2% during the first quarter. Great Lakes Advisors LLC now owns 162,288 shares of the biopharmaceutical company's stock worth $10,356,000 after purchasing an additional 98,190 shares during the period. Fred Alger Management LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth $516,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth $266,000. Redwood Investments LLC grew its holdings in shares of Halozyme Therapeutics by 25.3% during the first quarter. Redwood Investments LLC now owns 40,335 shares of the biopharmaceutical company's stock valued at $2,574,000 after buying an additional 8,146 shares in the last quarter. Finally, Teza Capital Management LLC purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at $573,000. Institutional investors own 97.79% of the company's stock.

Insider Buying and Selling

In related news, CFO Nicole Labrosse sold 20,000 shares of the business's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the transaction, the chief financial officer owned 24,306 shares of the company's stock, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $46,598,493.69. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 124,000 shares of company stock valued at $7,830,320. Insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on HALO shares. Wall Street Zen downgraded Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Zacks Research upgraded Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. JMP Securities lifted their price target on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a report on Wednesday, August 6th. Finally, HC Wainwright lifted their price target on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of "Hold" and an average target price of $67.11.

Halozyme Therapeutics Stock Down 0.8%

NASDAQ HALO traded down $0.63 on Friday, reaching $76.90. The stock had a trading volume of 1,121,085 shares, compared to its average volume of 1,930,531. The business has a 50 day moving average price of $65.11 and a 200 day moving average price of $60.45. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $77.60. The company has a market capitalization of $8.99 billion, a price-to-earnings ratio of 17.60, a P/E/G ratio of 0.43 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the previous year, the company posted $0.91 earnings per share. The business's quarterly revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.